Ad-hoc | 6 July 2001 07:11

MorphoSys AG english

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorphoSys Appoints New Supervisory Board Member Director of Pharmaceutical Development, Novartis AG, appointed Martinsried, Munich/Germany, July 6, 2001 – MorphoSys AG (Neuer Markt: MOR) announced today that at its annual shareholder meeting yesterday, the Companys shareholders confirmed the appointment of Dr. Jörg Reinhardt to the MorphoSys supervisory board. In his current position as Director of Pharmaceutical Development and member of the Executive Committee at Novartis Pharma, Dr. Reinhardt is responsible for worldwide pre-clinical and clinical drug development, clinical pharmacology, regulatory affairs and project management. Dr. Reinhardts extensive knowledge in product development will play an important role at MorphoSys as the Company builds its internal product pipeline. In addition to the confirmation of Dr. Reinhardts appointment to the supervisory board, all other management proposals of the shareholder assembly agenda were passed at the meeting, which took place in Planegg/Munich, Germany. end of ad hoc announcement (c) DGAP 06.07.2001 ——————————————————————————– WKN: 663200; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 060711 Jul 01